current on stereotactic body radiation therapy for pancreatic cancer.

: Pancreatic cancer is a formidable malignancy with poor outcomes. The majority of patients are unable to undergo resection, which remains the only potentially curative treatment option. The management of locally advanced (unresectable) pancreatic cancer is controversial; however, treatment with either chemotherapy or chemoradiation is associated with high rates of local tumor progression and metastases development, resulting in low survival rates. An emerging local modality is stereotactic body radiation therapy (SBRT), which uses image-guided, conformal, high-dose radiation. SBRT has demonstrated promising local control rates and resultant quality of life with acceptable rates of toxicity. Over the past decade, increasing clinical experience and data have supported SBRT as a local treatment modality. Nevertheless, additional research is required to further evaluate the role of SBRT and improve upon the per-sistently poor outcomes associated with pancreatic cancer. This review discusses the existing clinical experience and technical implementation of SBRT for pancreatic cancer and highlights the directions for ongoing and future studies.

[1]  David Goldstein,et al.  Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. , 2016, JAMA.

[2]  Daniel T Chang,et al.  Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients With Pancreatic Adenocarcinoma Treated With SBRT , 2016, American journal of clinical oncology.

[3]  T. Strom,et al.  Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma , 2015, Acta oncologica.

[4]  J. Cameron,et al.  The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience , 2015, Annals of Surgical Oncology.

[5]  Albert C. Koong,et al.  Phase 2 Multi-institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma , 2014, Cancer.

[6]  A. Koong,et al.  Stereotactic body radiation therapy in pancreatic cancer: the new frontier , 2014, Expert review of anticancer therapy.

[7]  Jeffrey W. Clark,et al.  A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. , 2014, International journal of radiation oncology, biology, physics.

[8]  T. Pawlik,et al.  Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy. , 2014, International journal of radiation oncology, biology, physics.

[9]  Donghui Li,et al.  Biomarkers of TGF-β Signaling Pathway and Prognosis of Pancreatic Cancer , 2014, PloS one.

[10]  A. Krasinskas,et al.  Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer , 2013, Radiation oncology.

[11]  M. Scorsetti,et al.  SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience , 2013, Radiation oncology.

[12]  E. Mok,et al.  Dosimetric analysis of organs at risk during expiratory gating in stereotactic body radiation therapy for pancreatic cancer. , 2013, International journal of radiation oncology, biology, physics.

[13]  J. Marshall,et al.  Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety , 2013, Radiation oncology.

[14]  D. Heron,et al.  Adjuvant Stereotactic Body Radiotherapy for Resected Pancreatic Adenocarcinoma with Close or Positive Margins , 2012, Journal of Gastrointestinal Cancer.

[15]  R. Timmerman,et al.  The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology , 2011, Clinical & developmental immunology.

[16]  M. Scorsetti,et al.  Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments , 2011, Radiation oncology.

[17]  T. Desser,et al.  Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. , 2011, International journal of radiation oncology, biology, physics.

[18]  K. Lillemoe,et al.  A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation , 2011, Annals of surgery.

[19]  Gang Li,et al.  Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. , 2011, Surgery.

[20]  H. Friess,et al.  Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. , 2010, JAMA.

[21]  A. Koong,et al.  18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. , 2010, International journal of radiation oncology, biology, physics.

[22]  Paolo Francescon,et al.  Unresectable Locally Advanced Pancreatic Cancer: A Multimodal Treatment Using Neoadjuvant Chemoradiotherapy (Gemcitabine Plus Stereotactic Radiosurgery) and Subsequent Surgical Exploration , 2010, Annals of Surgical Oncology.

[23]  J. Norton,et al.  Interfractional uncertainty in the treatment of pancreatic cancer with radiation. , 2010, International journal of radiation oncology, biology, physics.

[24]  Alison P. Klein,et al.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Lockwood,et al.  Phase I study of individualized stereotactic body radiotherapy of liver metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Desser,et al.  Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. , 2008, International journal of radiation oncology, biology, physics.

[27]  E. Jaffee,et al.  Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation , 2008, Clinical Cancer Research.

[28]  E. Touboul,et al.  Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Quynh-Thu Le,et al.  Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. , 2005, International journal of radiation oncology, biology, physics.

[30]  H. von der Maase,et al.  Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  Jeffrey W. Clark,et al.  Long-term Results of Intraoperative Electron Beam Irradiation (IOERT) for Patients With Unresectable Pancreatic Cancer , 2005, Annals of surgery.

[32]  Albert C Koong,et al.  Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. , 2004, International journal of radiation oncology, biology, physics.

[33]  Joel G Fletcher,et al.  Pancreatic malignancy: value of arterial, pancreatic, and hepatic phase imaging with multi-detector row CT. , 2003, Radiology.

[34]  S. Ellenberg,et al.  Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. , 1985, Archives of surgery.

[35]  The University of Maryland , 1883, The American journal of dental science.

[36]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[37]  E. Diamandis,et al.  Pancreatic cancer. , 2013, Clinical chemistry.

[38]  M. Mino‐Kenudson,et al.  Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. , 2011, International journal of radiation oncology, biology, physics.

[39]  T. Eberlein Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial , 2008 .

[40]  N. Dubrawsky Cancer statistics , 2022 .